Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms

Journal of Medicinal Chemistry

Volumn 60, Issue 1, 2017, Pages 290-306

  Tong, Ling ^a   Yu, Wensheng ^a   Chen, Lei ^a   Selyutin, Oleg ^a   Dwyer, Michael P ^a   Nair, Anilkumar G ^a   Mazzola, Robert ^a   Kim, Jae Hun ^a   Sha, Deyou ^a   Yin, Jingjun ^a   Ruck, Rebecca T ^a   Davies, Ian W ^a   Hu, Bin ^c   Zhong, Bin ^c   Hao, Jinglai ^c   Ji, Tao ^c   Zan, Shuai ^c   Liu, Rong ^a   Agrawal, Sony ^a   Xia, Ellen ^a   Curry, Stephanie ^a   McMonagle, Patricia ^a   Bystol, Karin ^a   Lahser, Frederick ^a   Carr, Donna ^a   Rokosz, Laura ^a   Ingravallo, Paul ^a   Chen, Shiying ^a   Feng, Kung I ^b   Cartwright, Mark ^b   Asante Appiah, Ernest ^a   Kozlowski, Joseph A ^a   more..

^a Department of Medicinal Chemistry ^*  (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c WUXI APPTEC   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL N,N' [[1 FLUORO 6 [3 (PROPAN 2 YL) 1,2 OXAZOL 5 YL] 6H INDOLO[1,2 C][1,3]BENZOXAZINE 3,10 DIYL]BIS[1H IMIDAZOLE 5,2 DIYL PYRROLIDINE 2,1 DIYL(3 METHYL 1 OXOBUTANE 1,2 DIYL)]]DICARBAMATE; IMIDAZOLE; INDOLE; METHYL [1 [3[5 [6 (2 CYCLOPROPYL 1,3 THIAZOL 5 YL) 1 FLUORO 3 [2 [1 [2 [( METHOXYCARBONYL)AMINO] 3 METHYL]BUTANOYL]PYRROLIDIN 2 YL] 1H IMIDAZOL 5 YL] 6H INDOLO[1,2 C][1,3]BENZOXAZIN 10 YL] 1H IMIDAZOLE 2 YL] 2 AZABICYCLO[3.1.0]HEXAN 2 YL] 3 METHYL 1; NONSTRUCTURAL PROTEIN 5A INHIBITOR; PROLINE; RUZASVIR; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; FUSED HETEROCYCLIC RINGS; NS-5 PROTEIN, HEPATITIS C VIRUS; PYRROLIDINE DERIVATIVE; THIAZOLE DERIVATIVE; VIRAL PROTEIN;

ANIMAL EXPERIMENT; ANTIVIRAL RESISTANCE; AREA UNDER THE CURVE; ARTICLE; DRUG POTENCY; DRUG SCREENING; HEPATITIS C; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PHARMACOKINETIC PARAMETERS; RAT; STRUCTURE ACTIVITY RELATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DOG; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; HAPLORHINI; HEPACIVIRUS; HUMAN;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; DOGS; HAPLORHINI; HEPACIVIRUS; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; POLYMORPHISM, GENETIC; PYRROLIDINES; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85018428000     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b01310     Document Type: Article

References (33)

1. Liang, J. T.; Hoofnagle, J. H. Hepatitis C; Biomedical Research Reports; Academic Press: London, U.K., 2000; pp 185-203.
2. Mohd Hanafiah, K.; Groeger, J.; Flaxman, A. D.; Wiersma, S. T. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence Hepatology 2013, 57, 1333-1342 10.1002/hep.26141
3. For a review on DAAs see the following: Holmes, J.; Thompson, A. Interferon-Free combination therapies for the treatment of hepatitis C: current insights Hepatic Med. 2015, 51-70 10.2147/HMER.S55864
4. van der Meer, A.; Veldt, B.; Feld, J.; Wedemeyer, H.; Dufour, J.; Lammert, F.; Duarte-Rojo, A.; Heathcote, E.; Manns, M.; Kuske, L. et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis JAMA 2012, 308, 2584-2593 10.1001/jama.2012.144878
5. Smith, D. B.; BukH, J.; Kuiken, C.; Muerhoff, A. S.; Rice, C. M.; Stapleton, J. T.; Simmonds, P. Expanded classification of hepatitis C virus inti 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource Hepatology 2014, 59 ( 1 ) 318-327 10.1002/hep.26744
6. Coburn, C. A.; Meinke, P. T.; Chang, W.; Fandozzi, C. M.; Graham, D. J.; Hu, B.; Huang, Q.; Kargman, S.; Kozlowski, J.; Liu, R.; McCauley, J. A.; Nomeir, A. A.; Soll, R. M.; Vacca, J. P.; Wang, D.; Wu, H.; Zhong, B.; Olsen, D. B.; Ludmerer, S. W. Discovery of MK-8742: an HCV NS5A inhibitor with broad genotype activity ChemMedChem 2013, 8, 1930-1940 10.1002/cmdc.201300343
7. Yu, W.; Coburn, C. A.; Nair, A. G.; Wong, M.; Tong, L.; Dwyer, M. P.; Hu, B.; Zhong, B.; Hao, J.; Yang, D.-Y.; Selyutin, O.; Jiang, Y.; Rosenblum, S. B.; Kim, S. H.; Lavey, B. J.; Zhou, G.; Rizvi, R.; Shankar, B. B.; Zeng, Q.; Chen, L.; Agrawal, S.; Carr, D.; Rokosz, L.; Liu, R.; Curry, S.; McMonagle, P.; Ingravallo, P.; Lahser, F.; Asante-Appiah, E.; Nomeir, A.; Kozlowski, J. A. Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742 Bioorg. Med. Chem. Lett. 2016, 26, 3800-3805 10.1016/j.bmcl.2016.05.041
8. Yu, W.; Coburn, C. A.; Nair, A. G.; Wong, M.; Rosenblum, S. B.; Zhou, G.; Dwyer, M. P.; Tong, L.; Hu, B.; Zhong, B.; Hao, J.; Ji, T.; Zan, S.; Kim, S. H.; Zeng, Q.; Selyutin, O.; Chen, L.; Masse, F.; Agrawal, S.; Liu, R.; Xia, E.; Zhai, Y.; Curry, S.; McMonagle, P.; Ingravallo, P.; Asante-Appiah, E.; Lin, M.; Kozlowski, J. A. Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742 Bioorg. Med. Chem. Lett. 2016, 26, 3414-3420 10.1016/j.bmcl.2016.06.056
9. Yu, W.; Tong, L.; Hu, B.; Zhong, B.; Hao, J.; Ji, T.; Zan, S.; Coburn, C. A.; Selyutin, O.; Chen, L.; Masse, F.; Rokosz, L.; Liu, R.; Curry, S.; McMonagle, P.; Ingravallo, P.; Asante-Appiah, E.; Chen, S.; Kozlowski, J. A. Discovery of chromane containing HCV NS5A inhibitors with improved potency against resistance associate variants. J. Med. Chem. 2016, ASAP. DOI: 10.1021/acs.jmedchem.6b01234.
10. Yu, W.; Zhou, G.; Coburn, C. A.; Zeng, Q.; Tong, L.; Dwyer, M. P.; Chen, L.; Mazzola, R.; Kim, J.-H.; Sha, D.; Selyutin, O.; Rosenblum, S. B.; Lavey, B.; Nair, A. G.; Kim, S. H.; Keertikar, K. M.; Masse, F.; Agrawal, S.; Liu, R.; Xia, E.; Zhai, Y.; Curry, S.; McMonagle, P.; Ingravallo, P.; Asante-Appiah, E.; Chen, S.; Kozlowski, J. A. Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742 Bioorg. Med. Chem. Lett. 2016, 26, 4851-4856 10.1016/j.bmcl.2016.08.002
11. Tong, L.; Yu, W.; Coburn, C. A.; Meinke, P. T.; Nair, A. G.; Dwyer, M. P.; Chen, L.; Selyutin, O.; Rosenblum, S. B.; Jiang, Y.; Fells, J.; Hu, B.; Zhong, B.; Soll, R. M.; Liu, R.; Agrawal, S.; Xia, E.; Zhai, Y.; Kong, R.; Ingravallo, P.; Nomeir, A.; Asante-Appiah, E.; Kozlowski, J. A. Alternative Core Development Around the HCV NS5A Inhibitor MK-8742 Scaffold Bioorg. Med. Chem. Lett. 2016, 26, 5132-5137 10.1016/j.bmcl.2016.07.057
12. Tong, L.; Yu, W.; Coburn, C. A.; Chen, L.; Selyutin, O.; Zeng, Q.; Dwyer, M. P.; Nair, A. G.; Shankar, B. B.; Kim, S. H.; Yang, D.-Y.; Rosenblum, S. B.; Ruck, R. T.; Davies, I. W.; Hu, B.; Zhong, B.; Hao, J.; Ji, T.; Zan, S.; Liu, R.; Agrawal, S.; Carr, D.; Curry, S.; McMonagle, P.; Bystol, K.; Lahser, F.; Ingravallo, P.; Chen, S.; Asante-Appiah, E.; Kozlowski, J. A. Structure-Activity Relationships of Proline Modifications Around the Tetracyclic-indole Class of NS5A Inhibitors Bioorg. Med. Chem. Lett. 2016, 26, 5354-5360 10.1016/j.bmcl.2016.08.097
13. Scheel, T.; Rice, C. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat. Med. 2013, 19, 837-849 10.1038/nm.3248
14. Gao, M.; Nettles, R.; Belema, M.; Snyder, L.; Nguyen, V.; Fridell, R.; Serrano-Wu, M.; Langley, D.; Sun, J.; O’Boyle, D., II et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 2010, 465, 96-100 10.1038/nature08960
15. Nettles, R.; Gao, M.; Bifano, M.; Chung, E.; Persson, A.; Marbury, T.; Goldwater, R.; DeMicco, M.; Rodriguez-Torres, M.; Vutikullird, A. et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 2011, 54, 1956-1965 10.1002/hep.24609
16. Belema, M.; Nguyen, V.; Bachand, C.; Deon, D.; Goodrich, J.; James, C.; Lavoie, R.; Lopez, O.; Martel, A.; Romine, J. et al. Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir J. Med. Chem. 2014, 57, 2013-2032 10.1021/jm401836p
17. Lok, A. Hepatitis C virus NS5A inhibitors and drug resistance mutations Clin. Liver Dis. 2013, 17, 111-121 10.1016/j.cld.2012.09.006
18. Pawlotsky, J.-M. NS5A inhibitors in the treatment of hepatitis C J. Hepatol. 2013, 59, 375-382 10.1016/j.jhep.2013.03.030
19. Belda, O.; Targett-Adams, P. Small molecule inhibitors of the hepatitis C virus-encoded NS5A protein Virus Res. 2012, 170, 1-14 10.1016/j.virusres.2012.09.007
20. Cordek, D. G.; Bechtel, J. T.; Maynard, A. T.; Kazmierski, W. M.; Cameron, C. E. Targeting the NS5A protein of HCV: an emerging option Drugs Future 2011, 36, 691-711 10.1358/dof.2011.036.09.1641618
21. Schmitz, U.; Tan, S.-L. NS5A-From obscurity to new target for HCV therapy Recent Pat. Anti-Infect. Drug Discovery 2008, 3, 77-92 10.2174/157489108784746597
22. Schinazi, R. F.; Bassit, L.; Gavegnano, C. HCV drug discovery aimed at viral eradication J. Viral Hepat. 2010, 17, 77-90 10.1111/j.1365-2893.2009.01246.x
23. Link, J. O.; Taylor, J. G.; Xu, L.; Mitchell, M.; Guo, H.; Liu, H.; Kato, D.; Kirschberg, T.; Sun, J.; Squires, N.; Parrish, J.; Keller, T.; Yang, Z.; Yang, C.; Matles, M.; Wang, Y.; Wang, K.; Cheng, G.; Tian, Y.; Mogalian, E.; Mondou, E.; Cornpropst, M.; Perry, J.; Desai, M. C. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection J. Med. Chem. 2014, 57 ( 5 ) 2033-2046 10.1021/jm401499g
24. DeGoey, D.; Randolph, J.; Liu, D.; Pratt, J.; Hutchins, C.; Donner, P.; Krueger, A.; Matulenko, M.; Patel, S.; Motter, C. et al. Discovery of ABT-267, A Pan-genotypic inhibitor of HCV NS5A J. Med. Chem. 2014, 57, 2047-205 10.1021/jm401398x
25. Younossi, Z. M.; Stepanova, M.; Feld, J.; Zeuzem, S.; Jacobson, I.; Agarwal, K.; Hezode, C.; Nader, F.; Henry, L.; Hunt, S. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: results from ASTRAL-1 placebo-controlled trial J. Hepatol. 2016, 65, 33-39 10.1016/j.jhep.2016.02.042
26. Yu, W.; Tong, L.; Kozlowski, J. A.; Selyutin, O.; Chen, L.; Kim, J.-H.; Sha, D.; Rizvi, R.; Shankar, B.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Wei, W.; Ji, T.; Zan, S. Preparation of thiazolyl-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection. Patent WO 2014110687 A1, 2014.
27. Neau, E.; Dansette, P.; Andronik, V.; Mansuy, D. hydroxylation of the thiophene ring by hepatic monooxygenases Biochem. Pharmacol. 1990, 39, 1101-1107 10.1016/0006-2952(90)90290-2
28. McMurtry, R.; Mitchell, J. renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephaloridine Toxicol. Appl. Pharmacol. 1977, 42, 285-300 10.1016/0041-008X(77)90005-9
29. Dansette, P.; Amar, C.; Smith, C.; Pons, C.; Mansuy, D. Oxidative activation of the thiophene ring by hepatic enzymes Biochem. Pharmacol. 1990, 39, 911-918 10.1016/0006-2952(90)90207-2
30. Kozlowski, J. A.; Rosenblum, S. B.; Coburn, C. A.; Shankar, B. B.; Nair, A. G.; Chen, L.; Dwyer, M. P.; Jiang, Y.; Keertikar, K. M.; Lavey, B. J.; Selyutin, O. B.; Tong, L.; Wong, M.; Yang, D.-Y.; Yu, W.; Zhou, G.; Wu, H.; Hu, B.; Zhong, B.; Sun, F.; Ji, T.; Shen, C. Preparation of tetracyclic indole derivatives for treatment of HCV infection. Patent WO 2012040923 A1, 2012.
31. Tong, L.; Yu, W.; Kozlowski, J. A.; Chen, L.; Selyutin, O.; Kim, S. H.; Dwyer, M.; Hu, B.; Zhong, B.; Wai, D.; Hao, J.; Shen, C.; Lei, Z.; Wang, W. Preparation of thiophene-substituted tetracyclic compounds end-capped with peptide derivatives as antiviral agents for treating hepatitis C virus infection. Patent WO 2014110706 A1, 2014.
32. Tong, X.; Bogen, S.; Chase, R.; Girijavallabhan, V.; Guo, Z.; Njoroge, F. G.; Prongay, A.; Saksena, A.; Skelton, A.; Xia, E.; Ralston, R. Characterization of resistance mutations against HCV ketoamide protease inhibitors Antiviral Res. 2008, 77 ( 3 ) 177-185 10.1016/j.antiviral.2007.11.010
33. Lahser, F. C.; Bystol, K.; Curry, S.; McMonagle, P.; Xia, E.; Ingravallo, P.; Chase, R.; Liu, R.; Black, T.; Hazuda, D.; Howe, A. Y. M.; Asante-Appiah, E. The combination of grazoprevir, a HCV NS3 protease inhibitor, and elbasvir, a HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons Antimicrob. Agents Chemother. 2016, 60, 2954-2964 10.1128/AAC.00051-16